Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ITOC 2022 | ITOC 2022 highlights: B-cell engineering for cancer treatment

Florian Märkl • 3 Oct 2022

ITOC 2022

General

Florian Märkl, Ludwig-Maximilians-Universität München, Munich, Germany, shares his highlights from Immunotherapy of Cancer (ITOC) Conference 2022, including a talk by Prof. Adi Barzel on B-cell engineering for cancer treatment. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The use of chemokines in cancer immunotherapy

The use of chemokines in cancer immunotherapy

Florian Märkl • 3 Oct 2022

Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma

Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma

Florian Märkl • 3 Oct 2022

The major hurdles of CAR-T cell therapy for solid tumors

The major hurdles of CAR-T cell therapy for solid tumors

Florian Märkl • 3 Oct 2022

Related Videos

Educational impact of a guideline-based hematology-oncology bootcamp curriculum

Educational impact of a guideline-based hematology-oncology bootcamp curriculum

Chinmay Jani • 31 May 2026

Reduced-dose radiation achieves local control in ATM-mutated cancers: Phase II results

Reduced-dose radiation achieves local control in ATM-mutated cancers: Phase II results

Amy Xu • 31 May 2026

Standardizing re-irradiation data and integrating patient biology

Standardizing re-irradiation data and integrating patient biology

Laure Marignol • 16 May 2026

Biology-driven approaches to safer re-irradiation strategies

Biology-driven approaches to safer re-irradiation strategies

Laure Marignol • 16 May 2026